Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sankyo Parke Davis Will Double Sales Force To Market GelTex Cholestagel

Executive Summary

Sankyo Parke Davis intends to double its sales force to support the marketing and sales of GelTex' cholesterol reduction agent Cholestagel (colesevelam).

You may also be interested in...



Sankyo/Forest Benicar Launch Set For May; Seventh Angiotensin II Inhibitor

Sankyo and Forest will launch the angiotensin II inhibitorBenicar (olmesartan) with a 1,200-person sales force

Sankyo/Forest Benicar Launch Set For May; Seventh Angiotensin II Inhibitor

Sankyo and Forest will launch the angiotensin II inhibitorBenicar (olmesartan) with a 1,200-person sales force

Genzyme Sees Renagel Clinical Data Driving Sales After Purchase Of GelTex

Renagel sales growth will be driven by results from cardiac calcification and morbidity and mortality trials, Genzyme Chairman Henri Termeer indicated during a Sept. 11 conference call announcing Genzyme's $1 bil. acquisition of GelTex.

Related Content

UsernamePublicRestriction

Register

ID014775

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel